Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(10%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
30%
Ph not_applicable
5
50%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
3(37.5%)
N/ANon-phased studies
5(62.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(3)
Terminated(2)
Other(2)

Detailed Status

Completed3
Not yet recruiting2
unknown2
Withdrawn2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (37.5%)
N/A5 (62.5%)

Trials by Status

active_not_recruiting110%
completed330%
not_yet_recruiting220%
unknown220%
withdrawn220%

Recent Activity

1 active trials
Showing 5 of 10
not_yet_recruitingphase_2

Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

NCT07244978
not_yet_recruitingphase_2

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

NCT07505186
active_not_recruitingphase_2

Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

NCT05659251
withdrawn

A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells

NCT05648188
completednot_applicable

Platelet Dysfunction in Blood Donors

NCT03599219
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07244978Phase 2

Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Not Yet Recruiting
NCT07505186Phase 2

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Not Yet Recruiting
NCT05659251Phase 2

Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Active Not Recruiting
NCT05648188

A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells

Withdrawn
NCT03599219Not Applicable

Platelet Dysfunction in Blood Donors

Completed
NCT03964155Not Applicable

Sampling in ARDS Patients Under Inhaled Sedation

Withdrawn
NCT04584593Not Applicable

Pilot Study to Detect SARS-CoV-2 Virus in Sperm

Unknown
NCT03305211Not Applicable

Biological Collection in Nephrology for the Study of the Links Between Kidney Disease, Immunity System and Cardiovascular Complications

Unknown
NCT02513758

Penetration and Compartimentation of HIV

Completed
NCT02686359Not Applicable

Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN)

Completed

All 10 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
10